The blogsters at In Vivo have weighed in on the news that Wyeth R&D chief Bob Ruffolo is retiring. He may have been tough to get along with, but the blog gives Ruffolo credit for some significant achievements in new drug approvals at a time most of the industry has been experiencing a long, dry spell. Ruffolo had early on noted the rising number of mid-stage trials that were failing, noting that the only sensible response was to increase the number of experimental therapies in the pipeline. All eyes now turn to the new R&F chief, Mikael Dolsten. Report